Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.95 |
| ▸ | DPYD | Q12882 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HBB | P68871 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymine SCHEMBL750450 | 0.97 | ATAD2 (1.00) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL15323914 | 0.97 | ATAD2 (1.00) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL29669526 | 0.97 | — | — | |
| Thymine SCHEMBL17201833 | 0.97 | ATAD2 (1.00) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL5235 | 0.97 | — | — | |
| Thymine SCHEMBL2724033 | 0.95 | ATAD2 (0.95) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL8649294 | 0.95 | ATAD2 (0.95) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL5176783 | 0.95 | ATAD2 (0.95) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL935833 | 0.95 | ATAD2 (0.95) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL31403209 | 0.95 | ATAD2 (0.95) | ATAD2DPYDMAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030119022-A1 | Recognition and cleavage at the DNA major groove | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-06-26 | — | — | US | disclosed |
| EP-1007519-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SAKALOSKY GEORGE P (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020037327-A1 | Treatment for cancer and compounds for use therein | SAKALOSKY GEORGE P (US) | 2002-03-28 | — | — | US | disclosed |
| US-6294678-B1 | AS ANTICARCINOGENIC AGENT | SAKALOSKY GEORGE P (US) | 2001-09-25 | — | — | US | disclosed |
| EP-1007519-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Sakalosky, George P. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1998030555-A1 | TREATMENT FOR CANCER AND COMPOUNDS FOR USE THEREWITH | SAKALOSKY GEORGE P (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037327-A1 | Treatment for cancer and compounds for use therein | SLC39A7, SLC30A6, SLC30A7 | ATAD2 3123/4885DPYD 60/4885MAPT 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.